The National Medicines Regulatory Authority of Sri Lanka projects a cost reduction of approximately 5.7 billion rupees regarding pharmaceutical imports scheduled for 2027. According to NMRA Chairman Dr. Ananda Wijewickrama, this financial efficiency stems from the regulation of 13 specific drug categories. These savings were realized through enhanced collaboration between the NMRA, the Medical Supplies Division, and the State Pharmaceuticals Corporation. Key factors contributing to this outcome include a more streamlined medicine registration process, improved procurement timelines, and more effective tender management. By optimizing coordination across these state institutions, the government aims to implement its national pricing policy more effectively. The authority also noted that broader price adjustments are currently being applied to a wider range of pharmaceutical products to ensure long-term fiscal sustainability in the healthcare sector.
Source : Newswire
Photo : Newswire
